NEW YORK (GenomeWeb News) — Cepheid said after the close of the market Thursday that its first quarter revenues grew 16 percent year over year driven by 26 percent growth in its clinical business.

In addition, the company disclosed during a conference call following the earnings release that it received Chinese Food and Drug Administration clearance for its Xpert MTB/RIF test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.